· Laquinimod - positive results presented from ALLEGRO Phase III trial
· TASQ - pivotal Phase III study initiated in the first quarter of 2011
· ANYARA - ongoing Phase III study expected to be concluded in 2012
· 57-57 - recommended Orphan Medicinal Product Status
· ISI - project proceeding according to plan
· RhuDex(TM) - preparations for continued clinical development in progress
· Net sales SEK 11.4 M (10.8)
· Operating loss SEK 229.0 M (loss: 219.6)
· Loss after tax SEK 221.1 (loss: 224.0)
· Loss per share for the period amounted to 3.38 (loss: 3.81)
· Private placement of SEK 375 M completed after the end of the period
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam
CFO
Tel. +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
